SCHEMBL29601190

SCHEMBL29601190

CSC(=CC(=O)c1ccccn1)SC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.55
MEN1 O00255 2/20 0.55
ALDH1A1 P00352 2/20 0.53
CES2 O00748 1/20 0.52
CES1 P23141 1/20 0.52
MAPT P10636 4/20 0.51
LMNA P02545 2/20 0.51
KDM4E B2RXH2 2/20 0.51
NPC1 O15118 2/20 0.51
PKM P14618 2/20 0.51
RAB9A P51151 2/20 0.51
L3MBTL1 Q9Y468 3/20 0.50
NAPRT Q6XQN6 1/20 0.50
P4HTM Q9NXG6 1/20 0.50
MAPK1 P28482 1/20 0.47
GPR52 Q9Y2T5 1/20 0.45
GSK3B P49841 1/20 0.44
KRAS P01116 1/20 0.43
MITF O75030 1/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11051347 1.00 KMT2A (0.55) KMT2AMEN1ALDH1A1CES2CES1
SCHEMBL10123164 0.81 ALDH1A1 (0.62) KMT2AMEN1ALDH1A1CES2CES1
SCHEMBL9564417 0.79 KDM4E (0.49) KMT2AMEN1ALDH1A1CES2CES1
SCHEMBL9564421 0.79 KDM4E (0.49) KMT2AMEN1ALDH1A1CES2CES1
SCHEMBL27039747 0.77 MAPT (0.58) KMT2AMEN1ALDH1A1CES2CES1
SCHEMBL20809657 0.77 ALDH1A1 (0.61) KMT2AMEN1ALDH1A1CES2CES1
SCHEMBL6244793 0.77 ALDH1A1 (0.61) KMT2AMEN1ALDH1A1CES2CES1
SCHEMBL3310895 0.76 MAPT (0.57) KMT2AMEN1ALDH1A1CES2CES1
SCHEMBL3310903 0.76 MAPT (0.57) KMT2AMEN1ALDH1A1CES2CES1
SCHEMBL3310899 0.76 MAPT (0.57) KMT2AMEN1ALDH1A1CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025891-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CELGENE CORPORATION 2024-01-25 US disclosed
EP-4232449-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES Celgene Corporation (US) 2023-08-30 EP disclosed
CN-116547282-A Heterocyclic compounds and their use for the treatment of helminth infections and diseases 新基公司 2023-08-04 CN disclosed
WO-2022087326-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CELGENE CORPORATION (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025891-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CYP8B1, PAH, INHA KMT2A 1911/4885MEN1 2606/4885ALDH1A1 717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.